Goli Pharmaceutical-B (01672) announced interim results. Shareholders' losses of 320 million yuan increased 263.5% year-on-year

According to the Zhitong Finance App, Goli Pharmaceutical-B (01672) announced results for the six months ended June 30, 2026. The group obtained total revenue of RMB 52.97 million (same unit), a year-on-year decrease of 48.9%; R&D costs of 342 million yuan, an increase of 132.7%; the company's equity shareholders should account for a loss of 320 million yuan, an increase of 263.5% over the previous year; and a loss of 30.74 points per share.

During the reporting period and up to the date of this announcement, the Group has made significant progress in the immunological disease pipeline: ASC50 is an IL-17A oral small molecule inhibitor. It has completed a US phase I SAD study in healthy subjects and a 28-day US phase I proof of concept (POC) (200 mg QD) study for patients with mild to moderate plaque psoriasis. Human data shows that ASC50 is expected to be the first and best-in-class oral small molecule IL-17A inhibitor. ASC51 is a potent, selective, once-daily oral STAT6 degrading agent and is eligible to submit an IND application to the FDA. ASC51 has completed all preparation studies required for FDA IND and is expected to become the second STAT6 oral small molecule degrader of its kind after KT-62. ASC52 is expected to be the best-in-class IL-17AA, AF, and FF oral cyclic peptide antagonist, and is expected to submit an IND to the FDA in the fourth quarter of 2026. ASC52 is expected to become the second IL-17AA, AF, and FF oral cyclic peptide antagonist after PN-881.

These achievements highlight the Group's strong R&D capabilities, outstanding execution, and long-term commitment to develop the world's best-in-class/first-of-its-kind pipeline drugs to address unmet clinical needs.

The sharp increase in R&D spending is mainly due to the Group's strategic commitment to advance its comprehensive metabolic disease pipeline, including small molecules and peptides.